{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:37:48Z","timestamp":1790739468933,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:00:00Z","timestamp":1571356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.omto.2019.10.004","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T20:53:56Z","timestamp":1571777636000},"page":"186-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["High-Affinity DARPin Allows Targeting of MeV to Glioblastoma Multiforme in Combination with Protease Targeting without Loss of Potency"],"prefix":"10.1016","volume":"15","author":[{"given":"Jan R.H.","family":"Hanauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich M.","family":"Lauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"M\u00fchlebach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2019.10.004_bib1","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/35022579","article-title":"SLAM (CDw150) is a cellular receptor for measles virus","volume":"406","author":"Tatsuo","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.omto.2019.10.004_bib2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nature10639","article-title":"Adherens junction protein nectin-4 is the epithelial receptor for measles virus","volume":"480","author":"M\u00fchlebach","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.omto.2019.10.004_bib3","doi-asserted-by":"crossref","first-page":"e1002240","DOI":"10.1371\/journal.ppat.1002240","article-title":"Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus","volume":"7","author":"Noyce","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.omto.2019.10.004_bib4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0092-8674(93)80071-L","article-title":"The human CD46 molecule is a receptor for measles virus (Edmonston strain)","volume":"75","author":"D\u00f6rig","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.omto.2019.10.004_bib5","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1128\/jvi.67.10.6025-6032.1993","article-title":"Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus","volume":"67","author":"Naniche","year":"1993","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2019.10.004_bib6","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1158\/0008-5472.CAN-04-0884","article-title":"High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus","volume":"64","author":"Anderson","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2019.10.004_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/1568009617666170222125035","article-title":"Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects","volume":"18","author":"Msaouel","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.omto.2019.10.004_bib8","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.mayocp.2014.04.003","article-title":"Remission of disseminated cancer after systemic oncolytic virotherapy","volume":"89","author":"Russell","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.omto.2019.10.004_bib9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/JVI.78.1.302-313.2004","article-title":"Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model","volume":"78","author":"Vongpunsawad","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2019.10.004_bib10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nbt942","article-title":"Antibody-targeted cell fusion","volume":"22","author":"Nakamura","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omto.2019.10.004_bib11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nbt1060","article-title":"Rescue and propagation of fully retargeted oncolytic measles viruses","volume":"23","author":"Nakamura","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omto.2019.10.004_bib12","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/mt.2013.16","article-title":"DARPin-targeting of measles virus. Unique bispecificity, effective oncolysis, and enhanced safety","volume":"21","author":"Friedrich","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2019.10.004_bib13","doi-asserted-by":"crossref","first-page":"16003","DOI":"10.1038\/mto.2016.3","article-title":"Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2\/neu or EpCAM as target receptors","volume":"3","author":"Hanauer","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2019.10.004_bib14","doi-asserted-by":"crossref","first-page":"11840","DOI":"10.1158\/0008-5472.CAN-06-1200","article-title":"Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity","volume":"66","author":"Allen","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2019.10.004_bib15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/sj.mt.6300105","article-title":"Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas","volume":"15","author":"Paraskevakou","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2019.10.004_bib16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5114\/fn.2012.32361","article-title":"Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features","volume":"50","author":"Karsy","year":"2012","journal-title":"Folia Neuropathol."},{"key":"10.1016\/j.omto.2019.10.004_bib17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.critrevonc.2017.01.005","article-title":"Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients","volume":"111","author":"Mehta","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.omto.2019.10.004_bib18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/neuonc\/noz043","article-title":"How to integrate immunotherapy into standard of care in glioblastoma","volume":"21","author":"Platten","year":"2019","journal-title":"Neuro-oncol."},{"key":"10.1016\/j.omto.2019.10.004_bib19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/313144a0","article-title":"Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin","volume":"313","author":"Libermann","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.omto.2019.10.004_bib20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/neuonc\/2.3.159","article-title":"Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements","volume":"2","author":"Frederick","year":"2000","journal-title":"Neuro-oncol."},{"key":"10.1016\/j.omto.2019.10.004_bib21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2017.04.007","article-title":"Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies","volume":"59","author":"Vogel","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.omto.2019.10.004_bib22","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.jmb.2008.07.085","article-title":"Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display","volume":"382","author":"Steiner","year":"2008","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.omto.2019.10.004_bib23","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jaad.2013.06.038","article-title":"Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis","volume":"69","author":"Ensslin","year":"2013","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"key":"10.1016\/j.omto.2019.10.004_bib24","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2478\/raon-2013-0014","article-title":"A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis","volume":"47","author":"Ocvirk","year":"2013","journal-title":"Radiol. Oncol."},{"key":"10.1016\/j.omto.2019.10.004_bib25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40257-013-0021-0","article-title":"Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic","volume":"14","author":"Rosen","year":"2013","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.omto.2019.10.004_bib26","doi-asserted-by":"crossref","first-page":"7694","DOI":"10.1158\/0008-5472.CAN-06-0538","article-title":"Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases","volume":"66","author":"Springfeld","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2019.10.004_bib27","doi-asserted-by":"crossref","first-page":"7620","DOI":"10.1158\/0008-5472.CAN-09-4650","article-title":"Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus","volume":"70","author":"M\u00fchlebach","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2019.10.004_bib28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.arcmed.2012.04.005","article-title":"Matrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma","volume":"43","author":"Kast","year":"2012","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.omto.2019.10.004_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jdermsci.2017.01.015","article-title":"Measles virus infection of human keratinocytes: Possible link between measles and atopic dermatitis","volume":"86","author":"Gourru-Lesimple","year":"2017","journal-title":"J.\u00a0Dermatol. Sci."},{"key":"10.1016\/j.omto.2019.10.004_bib30","doi-asserted-by":"crossref","first-page":"13149","DOI":"10.1128\/JVI.01415-07","article-title":"Affinity thresholds for membrane fusion triggering by viral glycoproteins","volume":"81","author":"Hasegawa","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2019.10.004_bib31","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/cgt.2014.25","article-title":"High scFv-receptor affinity does not enhance the antitumor activity of HER2-retargeted measles virus","volume":"21","author":"Suksanpaisan","year":"2014","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omto.2019.10.004_bib32","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.1128\/JVI.72.9.7420-7427.1998","article-title":"Measles virus spread and pathogenesis in genetically modified mice","volume":"72","author":"Mrkic","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2019.10.004_bib33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41541-019-0106-8","article-title":"Recombinant measles vaccine expressing malaria antigens induces long-term memory and protection in mice","volume":"4","author":"Mura","year":"2019","journal-title":"npj Vaccines"},{"key":"10.1016\/j.omto.2019.10.004_bib34","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1242\/dev.00664","article-title":"Mice humanised for the EGF receptor display hypomorphic phenotypes in skin, bone and heart","volume":"130","author":"Sibilia","year":"2003","journal-title":"Development"},{"key":"10.1016\/j.omto.2019.10.004_bib35","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1038\/s41467-018-07515-0","article-title":"Studies into the mechanism of measles-associated immune suppression during a measles outbreak in the Netherlands","volume":"9","author":"Laksono","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omto.2019.10.004_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00131-18","article-title":"In\u00a0Vitro Measles Virus Infection of Human Lymphocyte Subsets Demonstrates High Susceptibility and Permissiveness of both Naive and Memory B Cells","volume":"92","author":"Laksono","year":"2018","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2019.10.004_bib37","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2019.10.004_bib38","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1073\/pnas.91.16.7727","article-title":"A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity","volume":"91","author":"Nishikawa","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omto.2019.10.004_bib39","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1038\/sj.onc.1205610","article-title":"Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1","volume":"21","author":"Albertoni","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.omto.2019.10.004_bib40","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/mt.2008.128","article-title":"Targeted cell entry of lentiviral vectors","volume":"16","author":"Funke","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2019.10.004_bib41","doi-asserted-by":"crossref","first-page":"12971","DOI":"10.18632\/oncotarget.24191","article-title":"CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma","volume":"9","author":"Hanauer","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.omto.2019.10.004_bib42","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1006\/viro.1995.0075","article-title":"Preferential initiation at the second AUG of the measles virus F mRNA: a role for the long untranslated region","volume":"214","author":"Cathomen","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.omto.2019.10.004_bib43","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1128\/JVI.02389-05","article-title":"RNA polymerase II-controlled expression of antigenomic RNA enhances the rescue efficacies of two different members of the Mononegavirales independently of the site of viral genome replication","volume":"80","author":"Martin","year":"2006","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2019.10.004_bib44","first-page":"480","article-title":"Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Archiv f. experiment. Pathol. u","volume":"162","author":"K\u00e4rber","year":"1931","journal-title":"Pharmakol"},{"key":"10.1016\/j.omto.2019.10.004_bib45","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1128\/jvi.67.3.1493-1502.1993","article-title":"Cell fusion by the envelope glycoproteins of persistent measles viruses which caused lethal human brain disease","volume":"67","author":"Cattaneo","year":"1993","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2019.10.004_bib46","first-page":"3140","article-title":"Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas","volume":"55","author":"Wikstrand","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2019.10.004_bib47","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1006\/viro.1999.0064","article-title":"Inefficient measles virus budding in murine L.CD46 fibroblasts","volume":"265","author":"Vincent","year":"1999","journal-title":"Virology"}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770519300944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770519300944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:19:36Z","timestamp":1762496376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770519300944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":47,"alternative-id":["S2372770519300944"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2019.10.004","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-Affinity DARPin Allows Targeting of MeV to Glioblastoma Multiforme in Combination with Protease Targeting without Loss of Potency","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2019.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s).","name":"copyright","label":"Copyright"}]}}